JP7594161B2 - 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 - Google Patents

修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 Download PDF

Info

Publication number
JP7594161B2
JP7594161B2 JP2021538982A JP2021538982A JP7594161B2 JP 7594161 B2 JP7594161 B2 JP 7594161B2 JP 2021538982 A JP2021538982 A JP 2021538982A JP 2021538982 A JP2021538982 A JP 2021538982A JP 7594161 B2 JP7594161 B2 JP 7594161B2
Authority
JP
Japan
Prior art keywords
antigen
binding domain
polypeptide
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021538982A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516557A5 (https=
JP2022516557A (ja
Inventor
ジョン シー． ティマー
ブレンダン ピー． エッケルマン
ケイトリン マッケイブ ウィリス
フロリアン ジェイ． スルツマイアー
ブライアン アール． ベックランド
Original Assignee
インヒブルクス バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インヒブルクス バイオサイエンシズ インコーポレイテッド filed Critical インヒブルクス バイオサイエンシズ インコーポレイテッド
Publication of JP2022516557A publication Critical patent/JP2022516557A/ja
Publication of JP2022516557A5 publication Critical patent/JP2022516557A5/ja
Priority to JP2024185692A priority Critical patent/JP2025013911A/ja
Application granted granted Critical
Publication of JP7594161B2 publication Critical patent/JP7594161B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2021538982A 2019-01-07 2020-01-06 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 Active JP7594161B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024185692A JP2025013911A (ja) 2019-01-07 2024-10-22 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789075P 2019-01-07 2019-01-07
US62/789,075 2019-01-07
PCT/US2020/012296 WO2020146221A1 (en) 2019-01-07 2020-01-06 Polypeptides comprising modified il-2 polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024185692A Division JP2025013911A (ja) 2019-01-07 2024-10-22 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用

Publications (3)

Publication Number Publication Date
JP2022516557A JP2022516557A (ja) 2022-02-28
JP2022516557A5 JP2022516557A5 (https=) 2023-01-19
JP7594161B2 true JP7594161B2 (ja) 2024-12-04

Family

ID=69374426

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021538982A Active JP7594161B2 (ja) 2019-01-07 2020-01-06 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用
JP2024185692A Pending JP2025013911A (ja) 2019-01-07 2024-10-22 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024185692A Pending JP2025013911A (ja) 2019-01-07 2024-10-22 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用

Country Status (15)

Country Link
US (1) US20220089667A1 (https=)
EP (1) EP3908596A1 (https=)
JP (2) JP7594161B2 (https=)
KR (1) KR20210113265A (https=)
CN (1) CN113924311A (https=)
AR (1) AR117770A1 (https=)
AU (2) AU2020206672B2 (https=)
BR (1) BR112021012294A2 (https=)
CA (1) CA3125529A1 (https=)
CL (1) CL2021001779A1 (https=)
IL (1) IL284633A (https=)
MX (1) MX2021008147A (https=)
SG (1) SG11202106700WA (https=)
TW (1) TWI874345B (https=)
WO (1) WO2020146221A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240141853A (ko) 2017-08-03 2024-09-27 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
SG11202102930YA (en) 2018-11-08 2021-04-29 Synthorx Inc Interleukin 10 conjugates and uses thereof
EP3923974A4 (en) 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
EP4017540A1 (en) 2019-08-23 2022-06-29 Synthorx, Inc. Il-15 conjugates and uses thereof
US12234271B2 (en) 2019-09-10 2025-02-25 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
EP4174088A4 (en) * 2020-06-30 2024-01-24 GI Innovation, Inc. FUSION PROTEIN COMPRISING AN ANTI-LAG-3 AND IL-2 ANTIBODY AND USE THEREOF
US20230235005A1 (en) * 2020-07-02 2023-07-27 Inhibrx, Inc. Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
US20220144956A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
KR20230129983A (ko) * 2020-12-09 2023-09-11 애셔 바이오테라퓨틱스, 인크. 조작된 세포 요법을 위한 표적화된 사이토카인 구축물
CN112979782B (zh) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 一种多肽及其用途
JP2024512714A (ja) * 2021-03-31 2024-03-19 アンウィタ バイオサイエンシス， インク． 融合タンパク質、医薬組成物、及び治療適用
EP4373854A1 (en) * 2021-07-20 2024-05-29 Inhibrx, Inc. Cd8-binding polypeptides and uses thereof
TW202309102A (zh) * 2021-07-20 2023-03-01 美商英伊布里克斯公司 靶向cd8之經修飾il-2多肽及其用途
US20240376198A1 (en) * 2021-08-30 2024-11-14 Inhibrx, Inc. NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
JP2024534838A (ja) * 2021-08-30 2024-09-26 インヒブルクス インコーポレイテッド ＮＫｐ４６結合ポリペプチド及びその使用
EP4405487A4 (en) * 2021-09-26 2025-12-03 Wuxi Biologics Ireland Ltd IL-2 VARIANTS AND THEIR FUSING PROTEINS
WO2023133393A1 (en) * 2022-01-05 2023-07-13 Inhibrx, Inc. Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof
WO2024026449A2 (en) * 2022-07-28 2024-02-01 Proviva Therapeutics (Hong Kong) Limited Il-2 procytokine antibody fusion proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086798A2 (en) 2004-03-05 2005-09-22 Chiron Corporation Improved interleukin-2 muteins
CN102101885A (zh) 2010-09-01 2011-06-22 宋波 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
WO2016164937A2 (en) 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
SG192673A1 (en) * 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2013180200A1 (ja) * 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
WO2017121758A1 (en) * 2016-01-11 2017-07-20 Universität Zürich Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
US20200010528A1 (en) * 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
EP4516809A3 (en) * 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
US10676516B2 (en) * 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
CN111201035A (zh) * 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086798A2 (en) 2004-03-05 2005-09-22 Chiron Corporation Improved interleukin-2 muteins
CN102101885A (zh) 2010-09-01 2011-06-22 宋波 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
WO2016164937A2 (en) 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells

Also Published As

Publication number Publication date
EP3908596A1 (en) 2021-11-17
US20220089667A1 (en) 2022-03-24
CL2021001779A1 (es) 2022-03-04
JP2025013911A (ja) 2025-01-28
IL284633A (en) 2021-08-31
AU2020206672A1 (en) 2021-07-15
AU2025283608A1 (en) 2026-01-22
TWI874345B (zh) 2025-03-01
WO2020146221A1 (en) 2020-07-16
BR112021012294A2 (pt) 2021-09-08
AR117770A1 (es) 2021-08-25
KR20210113265A (ko) 2021-09-15
SG11202106700WA (en) 2021-07-29
CN113924311A (zh) 2022-01-11
TW202043259A (zh) 2020-12-01
JP2022516557A (ja) 2022-02-28
AU2020206672B2 (en) 2025-10-02
CA3125529A1 (en) 2020-07-16
MX2021008147A (es) 2021-08-11

Similar Documents

Publication Publication Date Title
JP7594161B2 (ja) 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用
JP7462611B2 (ja) Ｏｘ４０結合性ポリペプチド及びその使用
US20230235005A1 (en) Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
JP2024526835A (ja) Ｃｄ８結合ポリペプチド及びその使用
JP2024534838A (ja) ＮＫｐ４６結合ポリペプチド及びその使用
JP2025504363A (ja) γδＴ細胞結合ポリペプチド及びその使用
WO2023004305A1 (en) Cd8-targeted modified il-2 polypeptides and uses thereof
TW202328171A (zh) 靶向NKp46之經修飾之IL-2多肽及其用途
RU2849624C2 (ru) Полипептиды, содержащие модифицированный полипептид il-2, и их применения
US20250109203A1 (en) Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
TWI918596B (zh) Ox40結合多肽及其用途
WO2025048887A1 (en) Ox40 agonist therapy
HK40050757A (en) Ox40-binding polypeptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240924

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240925

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241022

R150 Certificate of patent or registration of utility model

Ref document number: 7594161

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150